b'Scientific Session Abstracts SUNDAY APRIL 21, 2024therapy and the use of native vein were protective against graft thrombosis. Despite their beneficial effect, we identified that 9.5% of the LEB population are not receiving statin and/or antiplatelet therapies, which serves as a potential quality improvement initiative. Our findings suggest that utilization of native vein conduit when possible, and promoting aggressive preoperative medical optimization including statin, aspirin and P2Y12 inhibitors may help avoid early graft occlusion in patients requiring lower extremity revascularization.42 NDANNUAL MEETING|APRIL 1921, 2024|OCEANSIDE, CA 79'